Arizona Health Sciences

Publications

Year of Publicationsort descending Title Faculty Association
1995 Detecting differences in 5-methylcytosine using restriction enzyme isoschizomers: an endogenous control for complete digestion. George Watts, Ph.D.
2001 Laminin-5-mediated gene expression in human prostate carcinoma cells. George Watts, Ph.D.
2001 cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. George Watts, Ph.D.
2002 Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. George Watts, Ph.D.
2002 Diverse actions of ovarian steroids in the serotonin neural system. John M. Streicher, PhD
2002 Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid beta (Abeta) in rabbit brain. Jeffrey J. Lochhead, PhD
2003 Low-level arsenite induced gene expression in HEK293 cells. George Watts, Ph.D.
2003 Characterization of reproductive steroid receptors and response to estrogen in a rat serotonergic cell line. John M. Streicher, PhD
2003 Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. George Watts, Ph.D.
2003 Cholesterol modifies classical conditioning of the rabbit (Oryctolagus cuniculus) nictitating membrane response. Jeffrey J. Lochhead, PhD
2004 The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. George Watts, Ph.D.
2004 Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations. George Watts, Ph.D.
2004 Proteasome-dependent degradation of cytochromes P450 2E1 and 2B1 expressed in tetracycline-regulated HeLa cells. John M. Streicher, PhD
2004 The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells. George Watts, Ph.D.
2005 Serotonin-related gene expression in female monkeys with individual sensitivity to stress. John M. Streicher, PhD
2005 Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Jeffrey J. Lochhead, PhD
2005 Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Jeffrey J. Lochhead, PhD
2005 Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Jeffrey J. Lochhead, PhD
2005 Water Quality and Cholesterol-induced pathology: differential effects of the M-1 muscarinic receptor agaonist AF267b on accumulation of Alzheimer-like Amyloid B in rabbit brain Jeffrey J. Lochhead, PhD
2006 AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells. George Watts, Ph.D.
2006 Epigenetic inactivation of the HOXA gene cluster in breast cancer. George Watts, Ph.D.
2006 Cholesterol, copper, and statin therapy in Alzheimer's disease Jeffrey J. Lochhead, PhD
2006 Pharmacogenomics of the polyamine analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane tetrahydrochloride, CGC-11093, in the colon adenocarcinoma cell line HCT1161. George Watts, Ph.D.
2007 Profiling of selenomethionine responsive genes in colon cancer by microarray analysis. George Watts, Ph.D.
2007 Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. George Watts, Ph.D.

Pages